Grant M. Gallagher

BARDA is committing over $1 billion for the agreement, which is dependent on approval or emergency use authorization by the US FDA.

Two studies will investigate monoclonal antibody-based treatments in both patients with mild disease and those who are hospitalized.

Dr. Patrick Soon-Shiong, CEO of ImmunityBio, initiates a conversation on the nature of the SARS-CoV-2 cytokine storm.

Adam Brufsky, MD, explains the insights years of research into SARS-CoV-1 may hold for SARS-CoV-2.

As the debate on hydroxychloroquine rages on, the FDA and a new advocacy group have sparred about the appropriateness of physicians prescribing the drug for COVID-19.

The trial will assess a monoclonal antibody based investigational treatment that may prevent COVID-19.

Collodial stability measures may predict whether a potential antibody-based treatment will work early on in the drug development process.

Dr. Anthony Fauci, CDC's Dr. Robert Redfield, & HHS' Admiral Brett Giroir spoke at a congressional hearing on coordinating the future of the national coronavirus response.

Peter Hotez, MD, PhD, recently authored a paper proposing a federally directed but state-adaptive reopening that aims for acceptable national suppression by October 1.

RedHill Biopharma has initiated a global phase 2/3 study in order to evaluate the use of opaganib in patients with severe COVID-19.

On Tuesday, Cain was said to be recovering, possibly reflecting the complex immune system stages of COVID-19 disease course.

People with travel links to China, Iran, and Italy may have accounted for nearly two-thirds of early COVID-19 cases in affected countries.

The method extracts SARS-CoV-2 RNA with the Mag-Bind Viral RNA Xpress Kit and the Hamilton MagEx STAR.

Dr. Adam Brufsky, an oncologist, compares viral and cancer immunity. Dr. Patrick Soon-Shiong connects the relation to COVID-19 vaccine research.

Infectious disease specialists explain how long term international cooperation with impacted societies can help to stop the cycle of Ebola outbreaks.

What happens if we don't get a COVID-19 vaccine? Patrick Soon-Shiong, MD, describes another potential route for research efforts, which could also supplement vaccine development.

Dr. Patrick Soon-Shiong and Dr. Adam Brufsky move on from the messenger RNA candidates to the adenovirus vaccines.

Dr. Patrick Soon-Shiong, Chairman and CEO of ImmunityBio, explains why T-cell immunity could be an important metric when evaluating experimental COVID-19 vaccines.

Weekly, we identify FDA product and drug recalls which have the potential to be clinically relevant.

Stroke associated with SARS-CoV-2 infection appears to be more dangerous for patients relative to the baseline risk from stroke, according to a study published earlier this month.

There is mixed international evidence about whether returning to school results in increased transmission or outbreaks, authors explained, and surges may be multiply determined.

Some ways of decontaminating N-95 respirator masks can degrade mask integrity, according to the authors of a recent study.

A benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection

Dr. Pol Vandenbroucke describes the individual and collective risks associated with rising antibiotic resistance.

Dr. Pol Vandenbroucke talks about what makes antibiotic stewardship so important to clinicians and researchers.

How might this new outbreak in Mbandaka differ from the recent outbreak in Kivu, a more conflict-prone region of the DRC?

The test is not FDA approved, but is instead authorized for emergency use in the context of the SARS-CoV-2 pandemic.

Dr. Pol Vandenbroucke explains how the development of health and civil society infrastructure around the world helps to slow antimicrobial resistance.

Dr. Pol Vandenbroucke describes the alarming global threat of antimicrobial resistance.

A single injection of the Ad5-vectored COVID-19 vaccine induced specific immune responses to the spike glycoprotein at day 28.